Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study

BACKGROUND: This study aimed to investigate the safety of sorafenib for the treatment of unresectable hepatocellular carcinoma in Chinese patients. METHODS: A subgroup of 345 Chinese patients from the international database of the Global Investigation of therapeutic DEcisions in hepatocellular carci...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Sheng-Long, Yang, Jiamei, Bie, Ping, Zhang, Shuijun, Chen, Xiaoping, Liu, Fengyong, Liu, Luming, Zhou, Jie, Dou, Kefeng, Hao, Chunyi, Shao, Guoliang, Xia, Qiang, Chen, Yajin, Yang, Jijin, Deng, Xiaxing, Liu, Yunpeng, Yuan, Yunfei, Fu, Zhiren, Nakajima, Keiko, Lv, Zhengguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834849/
https://www.ncbi.nlm.nih.gov/pubmed/29499662
http://dx.doi.org/10.1186/s12885-018-4144-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834849/
https://www.ncbi.nlm.nih.gov/pubmed/29499662
http://dx.doi.org/10.1186/s12885-018-4144-9

Ejemplares similares